Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Obstet Gynecol. 2017 Mar;129(3):439–447. doi: 10.1097/AOG.0000000000001867

Table 4.

Demographic and clinical characteristics of women with low-grade serous ovarian cancer after propensity score matching for utilization of chemotherapy.

Chemotherapy No
Chemotherapy
P
N 140 140
Mean Age [Years (SD)] 57.68 (15.71) 55.99 (15.90) 0.9
Race [N (%)] 0.6
White 115 (84.6) 120 (88.22)
African-America 16 (11.8) 11 (8.1)
Other 5 (3.7) 5 (3.7)
Period of Diagnosis [N
(%)]
0.8
2003–2005 57 (41.9) 52 (38.2)
2006–2008 49 (36.0) 50 (36.8)
2009–2011 30 (22.1) 34 (25.0)
Facility Type [N (%)] 0.7
Academic 55 (40.4) 59 (43.4)
Community 10 (7.4) 7 (5.1)
Comprehensive 71 (52.2) 70 (51.5)
Urban vs. Rural [N (%)] 0.8
Urban 120 (88.2) 123 (90.4)
Rural 2 (1.5) 2 (1.5)
Unknown 14 (10.3) 11 (8.1)
Registry Location [N (%)] 0.9
Northeast 23 (16.9) 20 (14.7)
Midwest 25 (18.4) 24 (17.6)
South 68 (50.0) 68 (50.0)
West 20 (14.7) 24 (17.6)
Income [N (%)] 1.0
1st Quartile 26 (19.1) 25 (18.4)
2nd Quartile 32 (23.5) 33 (24.3)
3rd Quartile 42 (30.9) 41 (30.1)
4th Quartile 30 (22.1) 30 (22.1)
Unknown 6 (4.4) 7 (5.1)
Insurance [N (%)] 0.7
None 10 (7.4) 9 (6.6)
Private 66 (48.5) 75 (55.1)
Medicare 41 (30.1) 40 (29.4)
Other Government 14 (10.3) 8 (5.9)
Unknown 5 (3.7) 4 (2.9)
Charlson/Deyo Score [N
(%)]
0.9
0 107 (78.7) 110 (80.9)
1 23 (16.9) 21 (15.4)
2 6 (4.4) 5 (3.67
Education Level [N (%)] 0.9
<7% 23 (16.9) 22 (16.2)
7–13% 39 (28.7) 44 (32.4)
13–21% 42 (30.9) 37 (27.2)
>21% 26 (19.1) 26 (19.1)
Unknown 6 (4.4) 7 (5.1)
Stage [N (%)] 0.5
IIIC 110 (80.9) 104 (76.5)
IV 26 (19.1) 32 (23.5)
Tumor size [N (%)] 1.0
<1cm 3 (2.2) 2 (1.5)
<2cm 9 (6.6) 7 (5.1)
<3cm 5 (3.7) 5 (3.7)
<4cm 1 (0.7) 1 (0.7)
<5cm 9 (6.6) 8 (5.9)
>5cm 58 (42.6) 65 (47.8)
Unknown 51 (37.5) 48 (35.3)
*

SD: Standard Deviation.